<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03914534</url>
  </required_header>
  <id_info>
    <org_study_id>Versión 1- BIO 088</org_study_id>
    <nct_id>NCT03914534</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Sodium Divalproate Tablets 500 mg</brief_title>
  <official_title>Bioequivalence Study of Sodium Divalproate Tablets 500 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tecnoquimicas</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tecnoquimicas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the bioequivalence of two valproic acid&#xD;
      formulations through the estimation of valproic acid in plasma samples, according to Food and&#xD;
      Drugs Administration (FDA), World Health Organization (WHO) and Colombian National Vigilance&#xD;
      Institute for Drugs and Food (INVIMA) guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single-center, open-label, four-period, two-treatment, two-sequence,&#xD;
      randomized, single-dose, crossover study. 30 healthy adults will be randomized to receive a&#xD;
      single dose (500 mg) of the test formulation of valproic acid and reference formulation of&#xD;
      valproic acid separately in each treatment period. There will be two treatment sequences (AB,&#xD;
      BA) and a 7 day washout between the two treatment periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Actual">February 12, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(AUC) Area Under the Curve 0-48</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Formulation of Valproic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valproic Acid tablets 500 mg Single dose administered in dosing period 1 or 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Formulation of Valproic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valcote tablets 500 mg Single dose administered in dosing period 1 or 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid 500 MG</intervention_name>
    <description>Administration of 500 mg of Valproic Acid</description>
    <arm_group_label>Test Formulation of Valproic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valcote 500 mg</intervention_name>
    <description>Administration of 500 mg of Valproic Acid</description>
    <arm_group_label>Reference Formulation of Valproic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and Women from 18 to 50 years old&#xD;
&#xD;
          -  Diagnosed as healthy after a clinical examination&#xD;
&#xD;
          -  BMI from 18 to 30 kg/m2&#xD;
&#xD;
          -  Not smoking for at least 3 months&#xD;
&#xD;
          -  To sign the informed consent&#xD;
&#xD;
          -  Not having participated in a similar study for at least 4 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal, cardiac immunological, dermatological, endocrine, gastrointestinal,&#xD;
             neurological or psychiatric condition&#xD;
&#xD;
          -  Hematologic disorders, specially anemia and polycythemia&#xD;
&#xD;
          -  Permanent or temporal pharmacological therapy, prescribed or not&#xD;
&#xD;
          -  Smoking for the last 3 months&#xD;
&#xD;
          -  Alcohol drinker more than once a week&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Drug hypersensitivity&#xD;
&#xD;
          -  Angioedema or anaphylaxis history&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  HIV o Hepatitis B diagnosed&#xD;
&#xD;
          -  Blood donor in the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universidad de la Sabana</name>
      <address>
        <city>Chía</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

